Friday, August 22, 2014

Titan implanting treatments for opioid dependence

Titan implanting treatments for opioid dependence

August 19, 2014 by · Leave a Comment 

Tweet In the continuing struggle to circumvent abuse of drugs to treat opioid dependence and enhance compliance regimes for better outcomes, Titan Pharmaceuticals (OTCBB:TTNP) is leading the race with a matchstick-sized implant of the approved drug, buprenorphine, which eases withdrawal symptoms. “With more than two million people in the U.S. suffering from opioid dependence, there […]

Leerink ups Intra-Cellular price target to $35

Leerink ups Intra-Cellular price target to $35

August 13, 2014 by · Leave a Comment 

Tweet Leerink Partners has raised its price target for “outperform-rated” Intra-Cellular Therapies (NASDAQ:ITCI) to $35 from $34 in assumed coverage. The stock closed at $15.98 on Tuesday. Intra-Cellular has announced that following a successful end of Phase 2 meeting with the FDA, it will conduct two pivotal Phase 3 trials with its ITI-007 drug candidate […]

Knight Therapeutics to sell priority review voucher

Knight Therapeutics to sell priority review voucher

August 12, 2014 by · Leave a Comment 

Tweet Knight Therapeutics (TSX:GUD) has entered into an arrangement with a global investment banking firm to sell its tropical disease priority review voucher (PRV). Developed by the FDA in 2007, a PRV is an incentive for companies to invest in new drugs and vaccines for neglected tropical diseases, and since 2012, a similar incentive exists […]

FDA eases Tekmira’s TKM-Ebola to partial clinical hold

FDA eases Tekmira’s TKM-Ebola to partial clinical hold

August 8, 2014 by · Leave a Comment 

Tweet The FDA has verbally confirmed that it has modified a full clinical hold on Tekmira Pharmaceuticals’ (NASDAQ:TKMR; TSX:TKM) TKM-Ebola Investigational New Drug application to a partial clinical hold. “We view this news as extremely positive, as this paves the way for TKM-Ebola to potentially be used in the treatment of individuals currently infected with […]

In conversation with Jason Mitakidis

In conversation with Jason Mitakidis

August 5, 2014 by · Leave a Comment 

Tweet As president and CEO of closely held Cyclica, Jason Mitakidis first became interested in computer simulation or, in silico, drug discovery while he was working as a bioinformatician at the Barcode of Life Project in 2006 and 2007. Prior to co-founding Cyclica in 2011, he gained several years of research experience in the fields […]

Clarus starts Tekmira Pharma at buy

Clarus starts Tekmira Pharma at buy

July 31, 2014 by · Leave a Comment 

Tweet Clarus Securities has initiated coverage of Tekmira Pharmaceuticals (NASDAQ:TKMR; TSX:TKM) with a “buy” rating and price target of $22.50, saying the company is delivering multiple paths to value. The stock closed at $12.73 on Wednesday. Tekmira is focused on RNA interference (RNAi) therapeutics and is a global leader in the field. The company develops […]

Verisante adds Drs. Beer and Werschler to its CAB

Verisante adds Drs. Beer and Werschler to its CAB

July 29, 2014 by · Leave a Comment 

Tweet Verisante Technology (OTCQX:VRSEF; TSX-V:VRS) has appointed Dr. Kenneth Beer and Dr. Wm. Philip Werschler to the company’s clinical advisory board. “Both Dr. Beer and Dr. Werschler have extensive experience assisting companies with setting up scientific advisory boards, advising with clinical studies and navigating the medical device regulatory regime in the U.S.,” Thomas Braun, president […]

Agile readies new confirmatory pivotal trial of contraceptive patch

Agile readies new confirmatory pivotal trial of contraceptive patch

July 29, 2014 by · Leave a Comment 

Tweet Agile Therapeutics (NASDAQ:AGRX) believes it has addressed the issues raised by the FDA last year about an initial pivotal trial of its Twirla contraceptive patch and is on track to treat the first patient in a new Phase 3 trial in the current quarter. “Following a complete response letter from the FDA in early […]

FDA clears Lorus Therapeutics IND for LOR-253

FDA clears Lorus Therapeutics IND for LOR-253

July 28, 2014 by · Leave a Comment 

Tweet The FDA has completed its review and cleared Lorus Therapeutics’ (OTC:LRUSF; TSX:LOR) investigational-new-drug application of LOR-253 for the treatment of hematologic malignancies, including acute myeloid leukemia, high-risk myelodysplastic syndromes, lymphomas and multiple myeloma. Clearance of the IND allows Lorus to initiate a Phase 1b, multicenter, open-label, clinical study of LOR-253 in patients with relapsed […]

Roth upgrades Prosensa Therapeutic to buy

Roth upgrades Prosensa Therapeutic to buy

July 28, 2014 by · Leave a Comment 

Tweet Roth Capital Partners has upgraded Prosensa Therapeutic NV (NASDAQ:RNA) to “buy,” with a $17 price target, reflecting evolving data in the treatment of Duchenne muscular dystrophy (DMD) and a conciliatory regulatory environment. The stock closed at $9.65 on Friday. Prosensa’s drisapersen treatment for DMD failed a Phase 3 trial last fall, prompting partner GlaxoSmithKline […]

Next Page »

Email Newsletters with Constant Contact
Google+